Drugs / Tree SLIT-tablet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04878354 | Apr 2021 → Jul 2023 | allergic disease | ALK-Abelló A/S | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | ALK-Abelló A/S | Results ALK’s pivotal phase 3 trial in children published in reputable scientific journal alk.net ↗
The reputable scientific journal, The Lancet Regional Health – Europe , has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis. |
| 2024-06-03 | ALK-Abelló A/S | Results ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies alk.net ↗
ALK presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen respiratory allergy. |
| 2019-06-24 | ALK-Abelló A/S | Regulatory ALK submits registration application for tree SLIT-tablet in Canada alk.net ↗
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today announced that the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities. |
| 2018-08-22 | ALK-Abelló A/S | Regulatory ALK submits registration application for tree SLIT-tablet in Europe alk.net ↗
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today announced that the European regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities via the decentralised procedure, with Germany as the reference member state. |
| 2017-09-14 | ALK-Abelló A/S | Results Successful Phase III trial for ALK's tree allergy SLIT-tablet alk.net ↗ |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | ALK-Abelló A/S | ALK’s pivotal phase 3 trial in children published in reputable scientific journal alk.net ↗ |
| 2024-06-03 | ALK-Abelló A/S | ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies alk.net ↗ |
| 2019-09-02 | ALK-Abelló A/S | Germany becomes first launch market for ALK’s tree SLIT-tablet alk.net ↗ |
| 2019-06-24 | ALK-Abelló A/S | ALK submits registration application for tree SLIT-tablet in Canada alk.net ↗ |
| 2019-06-07 | ALK-Abelló A/S | ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis alk.net ↗ |
| 2018-08-22 | ALK-Abelló A/S | ALK submits registration application for tree SLIT-tablet in Europe alk.net ↗ |
| 2017-09-14 | ALK-Abelló A/S | Successful Phase III trial for ALK's tree allergy SLIT-tablet alk.net ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tree SLIT-tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04878354 ↗ |